## Financial Review for the Year Ended March 31, 2024

Company name: RYOYO RYOSAN HOLDINGS, INC. (RYOYO ELECTRO CORPORATION)
Headquarters address: 12-22 Tsukiji 1-chome, Chuo-ku, Tokyo 104-8408 Japan

URL: <a href="https://www.rr-hds.co.jp/">https://www.rr-hds.co.jp/</a>

Stock exchange listing: Tokyo Stock Exchange Prime Section

Code number: 167A

Company representative: Moritaka Nakamura, President & Chief Executive Officer

Inquiries: Masayuki Takahashi, Executive General Manager, Administration Headquaters

Tel: +81-3-3543-7711 E-mail: irmanager@rr-hds.co.jp

Due date of annual shareholders meeting : June 28, 2024

Due date of starting delivery of dividends : May 31, 2024

Due date of submitting of financial statement : June 28, 2024

Supplementary materials for the quarterly financial results : Yes

Investor conference for the quarterly financial results

(for security analysts and institutional investors) : Yes

Note: Figures are rounded down to the nearest million yen.

1. Financial highlights for the year ended March 31, 2024 (2/1/2023-3/31/2024)

(1) Consolidated operating results

Note: Percentages indicated changes from the same period of previous year.

	Net sale	es	Operating	profit	Ordinary p	rofit
	Millions of yen	%	Millions of yen	%	Millions of yen	%
Year ended 3/31/24	148, 959	_	4, 679	_	9, 234	_
Year ended 1/31/23	129, 912	15. 9	4, 693	107. 9	4, 477	86. 5

Note: Comprehensive income

Year ended 3/31/24: 11,305 million yen ( - %) Year ended 1/31/23: 3,729 million yen (85.0%)

	Profit attributable to owners of parent	Net income per share	Fully diluted net income per share	Return on equity	Ordinary income to total assets	Operating income to net sales
	Millions of yen %	Yen	Yen	%	%	%
Year ended 3/31/24	7, 125 —	352. 64	_	14. 6	9.8	3. 1
Year ended 1/31/23	3, 056 63. 1	151. 46	151. 23	7. 0	5. 6	3. 6

(Reference) Investment profit/loss on equity method:

Year ended 3/31/24: 5,156 million yen Year ended 1/31/23: — million yen

### (2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of 3/31/24	99, 138	53, 250	53. 7	2, 633. 36
As of 1/31/23	88, 409	44, 725	50.6	2, 213. 66

(Reference) Equity

Year ended 3/31/24: 53,221 million yen Year ended 1/31/23: 44,697 million yen

### (3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at the end of the period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Year ended 3/31/24	12, 274	(17, 564)	(2, 680)	11, 579
Year ended $1/31/23$	(2, 553)	150	11, 549	19, 031

### 2. Dividends

	Cash	dividends per	share	Total		
	Six months ended	Year ended	Total	dividends Paid (Full Year)	Payout ratio	Dividends on equity
(Base date)	Yen	Yen	Yen	Millions of yen	%	%
Year ended 1/31/23	50.00	60.00	110.00	2, 221	72. 6	5. 1
Year ended 3/31/24	80.00	100.00	180.00	3, 637	51.0	7. 4

#### 4. Others

(1) Important changes in subsidiaries

(Change on specific subsidiaries with changes in scope of consolidation): None

Newly added: - Excluded: -

- (2) Changes in principles, procedures and method of presentation for consolidated financial statements
  - ① Changes in accounting policies: None
  - 2 Other changes: None
  - 3 Change in accounting estimate: None
  - (4) Restatement of revisions: None
- (3) Number of shares outstanding (common shares)
  - ① Number of shares of common shares issued as of:

(Including treasury shares)

March 31, 2024: 26, 800, 000 shares January 31, 2023: 26, 800, 000 shares

 ${f 2}$  Number of shares of treasury shares:

March 31, 2024: 6, 589, 495 shares January 31, 2023: 6, 608, 536 shares

3 Average number of shares outstanding as of:

March 31, 2024: 20, 205, 758 shares January 31, 2023: 20, 179, 911 shares (Reference) Non-consolidated financial review

1. Financial highlights for the year ended March 31, 2024 (2/1/2023-3/31/2024)

#### (1) Operating results

Note: Percentages indicated changes from the same period of previous year.

	Net sales	Operating profit	Ordinary profit
	Millions of yen %	Millions of yen %	Millions of yen %
Year ended 3/31/24	98, 156 —	3, 452 —	3, 713 —
Year ended 1/31/23	94, 297 15. 5	3, 498 105. 2	3, 264 51. 9

	Net income	Net income per share	Fully diluted net income per share
	Millions of yen %	Yen	Yen
Year ended 3/31/24	2, 133 —	105. 60	_
Year ended 1/31/23	2, 068 13. 5	102. 52	102. 36

#### (2) Financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of 3/31/24	82, 071	41, 136	50. 1	2, 034. 00
As of 1/31/23	76, 341	39, 729	52. 0	1, 966. 22

(Reference) Equity

Year ended 3/31/24: 41,108 million yen Year ended 1/31/23: 39,700 million yen

Indication regarding the implementation status of auditing procedure

This Financial Review is not subject to audit procedure under the Financial Instruments and Exchange Act.

\* This financial review is only the translation of Japanese version.

## Consolidated Balance Sheets

		(Millions of yen)
	As of January 31, 2023	As of March 31, 2024
	Amount	Amount
(Assets)		
Current Assets		
Cash and deposits	19, 031	11, 692
Notes and accounts receivable - trade, and contract assets	30, 966	30, 895
Electronically recorded monetary claims - operating	3, 886	4, 042
Merchandise and finished goods	23, 623	15, 719
Work in process	174	450
Other	1, 502	1, 062
Allowance for doubtful accounts	(1)	(1)
Total current assets	79, 183	63, 861
Non-current assets		
Property, plant and equipment		
Tools, furniture and fixtures, net	73	126
Land	5	5
Construction in progress	7	_
Other, net	139	212
Total property, plant and equipment	226	344
Intangible assets		
Goodwill	471	396
Other	361	690
Total Intangible assets	832	1, 086
Investments and other assets		
Investment securities	5, 308	8, 255
Shares of subsidiaries and associates	97	22, 362
Deferred tax assets	110	100
Retirement benefit asset	1, 589	1, 909
Other	1, 642	1, 395
Allowance for doubtful accounts	(582)	(176)
Total investments and other assets	8, 166	33, 845
Total noncurrent assets	9, 225	35, 276
Total assets	88, 409	99, 138
	· · · · · · · · · · · · · · · · · · ·	*

## Consolidated Balance Sheets

	As of January 31, 2023	As of March 31, 2024
	Amount	Amount
(Liabilities)		
Current liabilities		
Notes and accounts payable - trade	13, 366	13, 754
Short-term borrowings	25, 817	26, 365
Income taxes payable	1, 423	210
Accrued consumption taxes	143	444
Provision for bonuses	857	1, 022
Other	1, 048	1, 746
Total current liabilities	42, 657	43, 543
Non-current liabilities		
Deferred tax liabilities	603	1, 918
Retirement benefit liability	316	317
Other	106	108
Total noncurrent liabilities	1, 026	2, 344
Total liabilities	43, 683	45, 888
(Net assets)		
Shareholders' equity		
Share capital	13, 672	13, 672
Capital surplus	13, 336	13, 336
Retained earnings	32, 000	36, 296
Treasury shares	(17, 068)	(17, 020)
Total shareholders' equity	41, 940	46, 284
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	1, 805	4, 013
Deferred gains or losses on hedges	0	0
Foreign currency translation adjustment	1, 124	2, 972
Remeasurements of defined benefit plans	(173)	(49)
Total accumulated other comprehensive income	2, 756	6, 937
Share acquisition rights	28	28
Total net assets	44, 725	53, 250
Total liabilities and net assets	88, 409	99, 138

### Consolidated Statements of Income and Consolidated Comprehensive Statements of Income

(Consolidated Statement of Income)

(Consolidated Statement of Income)		(Willions of yen)
	Year ended January 31, 2023	Year ended March 31, 2024
	Amount	Amount
Net sales	129, 912	148, 959
Cost of sales	116, 328	133, 266
Gross profit	13, 583	15, 693
Selling, general and administrative expenses		
Provision of allowance for doubtful accounts	(3)	58
Salaries and bonuses	3, 400	4, 068
Provision for bonuses	746	896
Retirement benefit expenses	174	232
Rent expenses	414	477
Depreciation	145	177
Other	4, 011	5, 102
Total selling, general and administrative expenses	8, 889	11, 013
Operating profit	4, 693	4, 679
Non-operating income	.,	.,
Interest income	43	99
Dividend income	113	129
Share of profit of entities accounted for using equity method	_	5, 156
Other	28	27
Total non-operating income	185	5, 413
Non-operating expenses		5,
Interest expenses	185	434
Foreign exchange losses	151	325
Loss on abandonment of non-current assets	2	10
Other	61	87
Total non-operating expenses	401	857
Ordinary profit	4, 477	9, 234
Extraordinary income	1, 177	0,201
Gain on sales of investment securities	_	28
Reversal of allowance for doubtful accounts	_	22
Total extraordinary income	_	51
Extraordinary losses		
Loss on valuation of investment securities	105	_
Impairment losses	_	74
Management Integration related expenses	_	523
Total extraordinary losses	105	598
Profit before income taxes	4, 372	8, 687
Income taxes - current	1, 595	1, 197
Income taxes - deferred	(279)	365
Total income taxes	1, 316	1, 562
Profit	3, 056	7, 125
Profit attributable to owners of parent	3, 056	7, 125

### Consolidated Statements of Income and Consolidated Comprehensive Statements of Income

(Consolidated Comprehensive Statement of Income)

(control reacon comprehensive ocacomore of theome)		(militation of you)
	Year ended January 31, 2023	Year ended March 31, 2024
	Amount	Amount
Profit attributable to owners of parent	3, 056	7, 125
Other comprehensive income		
Valuation difference on available-for-sale securities	10	2, 055
Deferred gains or losses on hedges	0	(0)
Foreign currency translation adjustment	712	967
Remeasurements of defined benefit plans, net of tax	(51)	128
Share of other comprehensive income of entities accounted for using equity method	_	1, 029
Total other comprehensive income	672	4, 180
Comprehensive income	3, 729	11, 305
(Details)		
Comprehensive income attributable to owners of parent	3, 729	11, 305
Comprehensive income attributable to non-controlling interests	_	_

# Consolidated Statements of Changes in Net Assets Previous period (From February 1, 2022 to January 31, 2023 )

	Shareholders' equity					
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	
Balance at the beginning of current period	13, 672	13, 336	31, 164	(17, 978)	40, 194	
Changes during period						
Dividends of surplus			(2, 200)		(2, 200)	
Profit attributable to owners of parent			3, 056		3, 056	
Purchase of treasury shares				(1)	(1)	
Disposal of treasury shares		(0)		0	0	
Exercise of share acquisition rights		(210)		848	638	
Restricted stock payment		(13)		62	48	
Change in scope of consolidation			204		204	
Transfer from retained earnings to capital surplus		224	(224)		_	
Net changes in items other than shareholders' equity					_	
Total changes during period	_	_	835	909	1, 745	
Balance at end of period	13, 672	13, 336	32, 000	(17, 068)	41, 940	

	Accumulated other comprehensive income					
	Valuation difference on available-for -sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remesurements of defined benefit plans	Share acquisition rights	Total net assets
Balance at the beginning of current period	1, 794	(0)	412	(122)	30	42, 309
Changes during period						
Dividends of surplus						(2, 200)
Profit attributable to owners of parent						3, 056
Purchase of treasury shares						(1)
Disposal of treasury shares						0
Exercise of share acquisition rights						638
Restricted stock payment						48
Change in scope of consolidation						204
Transfer from retained earnings to capital surplus						_
Net changes in items other than shareholders' equity	10	0	712	(51)	(2)	670
Total changes during period	10	0	712	(51)	(2)	2, 416
Balance at end of period	1, 805	0	1, 124	(173)	28	44, 725

# Consolidated Statements of Changes in Net Assets Current period (From February 1, 2023 to March 31, 2024)

	Shareholders' equity						
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity		
Balance at the beginning of current period	13, 672	13, 336	32, 000	(17, 068)	41, 940		
Changes during period							
Dividends of surplus			(2, 828)		(2, 828)		
Profit attributable to owners of parent			7, 125		7, 125		
Purchase of treasury shares				(3)	(3)		
Restricted stock payment		(1)		51	49		
Transfer from retained earnings to capital surplus		1	(1)		_		
Net changes in items other than shareholders' equity					_		
Total changes during period	_		4, 295	48	4, 343		
Balance at end of period	13, 672	13, 336	36, 296	(17, 020)	46, 284		

	Accum	nulated other c				
	Valuation difference on available-for -sale securities	Deferred gains or losses on hedge	Foreign currency translation adjustment	Remesurements of defined benefit plans	Share acquisition rights	Total net assets
Balance at the beginning of current period	1, 805	0	1, 124	(173)	28	44, 725
Changes during period						
Dividends from surplus						(2, 828)
Profit attributable to owners of parent						7, 125
Purchase of treasury shares						(3)
Restricted stock payment						49
Transfer from retained earnings to capital surplus						-
Net changes of items other than shareholders' equity	2, 208	0	1, 847	124	_	4, 180
Total changes during period	2, 208	0	1, 847	124	_	8, 524
Balance at end of period	4, 013	0	2, 972	(49)	28	53, 250

## Consolidated Statements of Cash Flows

	(IVI)	llions of yen)
	Year ended	Year ended
	January 31, 2023	March 31, 2024
	Amount	Amount
I. Cash flows from operating activities		
Profit before income taxes	4, 372	8, 687
Depreciation	179	225
Impairment losses	_	74
Amortization of goodwill	64	74
Share of loss (profit) of entities accounted for using equity method	-	(5, 156)
Loss (gain) on sales and retirement of non-current assets	2	10
Share-based remuneration expenses	40	56
Loss (gain) on investments in investment partnerships	(6)	7
Foreign exchange losses (gains)	(112)	(410)
Increase (decrease) in provisions	346	142
Increase (decrease) in retirement benefit liability	11	12
Interest and dividend income	(157)	(229)
Interest expenses	185	434
Loss (gain) on sales of investment securities	-	(28)
Loss (gain) on valuation of investment securities	105	_
Decrease (increase) in trade receivables	(1, 193)	989
Decrease (increase) in inventories	(3, 505)	8, 133
Increase (decrease) in trade payables	(2, 070)	6
Increase (decrease) in accrued consumption taxes	105	312
Management Integration related expenses	-	523
Other, net	(261)	500
Subtotal	(1, 894)	14, 366
Interest and dividends received	148	950
Interest paid	(179)	(440)
Income taxes refund (paid)	(628)	(2, 326)
Integration related expenses paid	-	(276)
Net cash provided by (used in) operating activities	(2, 553)	12, 274
II. Cash flows from investing activities	(4.400)	(4.400)
Payments into time deposits	(1, 460)	(1, 499)
Proceeds from withdrawal of time deposits	1, 460	1, 393
Proceeds from redemption of securities	500	
Purchase of property, plant and equipment and intangible assets	(260)	(569)
Proceeds from sales of property, plant and equipment and intangible assets  Purchase of investment securities	(7)	0
Proceeds from sale of investment securities	(7)	(38)
Purchase of shares of subsidiaries and associates	_	41 (16, 798)
Proceeds from sale of shares of subsidiaries and associates	0	(10, 790)
Loan advances to subsidiaries and associates	(60)	_
Collection of loans receivable from subsidiaries and affiliates	(00)	22
Proceeds from distributions from investment partnerships	19	35
Purchase of insurance funds	(140)	(220)
Proceeds from cancellation of insurance funds	101	66
Other, net	(2)	0
Net cash provided by (used in) investing activities	150	(17, 564)
III. Cash flows from financing activities		(, 551)
Proceeds from short-term borrowings	193, 365	336, 174
Repayments of short-term borrowings	(180, 224)	(335, 996)
Dividends paid	(2, 195)	(2, 823)
Purchase of treasury shares	(1)	(3)
Proceeds from sale of treasury shares	0	_
Proceeds from disposal of treasury shares from exercise of subscription rights to shares	636	_
Repayments of lease liabilities	(30)	(31)
Net cash provided by (used in) financing activities	11, 549	(2, 680)
IV. Effect of exchange rate change on cash and cash equivalents	348	518
V. Net increase (decrease) in cash and cash equivalents	9, 494	(7, 451)
VI. Cash and cash equivalents at beginning of period	9, 204	19, 031
WI. Increase in cash and cash equivalents resulting from inclusion of subsidiaries in consolidation	332	
Wax. Cash and cash equivalents at end of period	19, 031	11, 579

## Consolidated Sales by Product

		ended 31, 2023	Year ended March 31, 2024		
	Amount	Composition(%)	Amount	Composition(%)	
Semiconductors/Devices	79, 151	60. 9	88, 961	59. 7	
ICT/Solutions	50, 760	39. 1	59, 998	40. 3	
Total	129, 912	100.0	148, 959	100.0	